Delivery Order SPE2DB22D2206-SPE2DB25FJS48
- Not listed
- The Defense Logistics Agency awarded a $9,272.65 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Repatha 140 mg/mL SureClick auto-injector pens, with an ultimate completion date of September 4, 2025. This non-set-aside competitive award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and running through December 2026. The pharmaceutical product will be delivered to...
- The Defense Logistics Agency awarded a $41,877.63 delivery order to AmerisourceBergen Drug Corp for Repatha 140 mg/mL SureClick auto-injector pens under a firm fixed price contract type. The award was made on September 2, 2025, with an ultimate completion date of September 3, 2025, and represents a non-set-aside competitive procurement. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as the place of performance for this transaction. This delivery order constitutes a...
- The Defense Logistics Agency awarded a delivery order valued at $1,041.42 to AmerisourceBergen Drug Corp for the supply of Repatha 140 mg/ml SureClick auto-injector pens, with an ultimate completion date of August 5, 2025. This non-set-aside, competitively awarded contract employs firm fixed price terms and represents a child delivery order under AmerisourceBergen's larger indefinite delivery contract with DLA Troop Support Medical. The product will be delivered to the company's facility in...
- The Defense Logistics Agency awarded a delivery order valued at $2,648.59 to AmerisourceBergen Drug Corp for Repatha 140 mg/ml SureClick auto-injector pens, with an ultimate completion date of September 12, 2025. This is a firm fixed-price, competitively awarded contract with no set-aside designation. The award reflects AmerisourceBergen's role as a critical pharmaceutical distributor supporting federal medical procurement, particularly for military and veteran healthcare systems. The place of...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a $3,696.37 firm fixed-price delivery order for Repatha 140 mg/ml SureClick auto-injector pens, with performance in Conshohocken, Pennsylvania and completion scheduled for November 12, 2025. This competitive award, issued on November 10, 2025, carries no set-aside designation and represents a child order under AmerisourceBergen's broader contract vehicle with DLA. This delivery order falls under AmerisourceBergen's substantial...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Repatha 140 mg/ml SureClick auto-injector pens, valued at $2,003.48. The award was made on October 30, 2025, under a firm fixed-price delivery order contract with an ultimate completion date of October 31, 2025. This non-set-aside delivery order will be fulfilled from AmerisourceBergen's Conshohocken, Pennsylvania facility, where the company maintains its corporate operations and serves as a...
- The Defense Logistics Agency awarded a delivery order valued at $91,225.90 to AmerisourceBergen Drug Corp for the supply of Repatha 140 mg/ml SureClick auto-injector pens. This firm fixed-price delivery order, issued on September 18, 2025, with an ultimate completion date of September 19, 2025, represents a non-competitive award under an existing contract vehicle. The work will be performed at AmerisourceBergen's Conshohocken, Pennsylvania facility, the company's corporate headquarters and a...
- The Defense Logistics Agency awarded a delivery order valued at $18,133.57 to AmerisourceBergen Drug Corp for Repatha 140 mg/ml SureClick auto-injector pens, with an ultimate completion date of September 10, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a single delivery order fulfillment. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, serves as a critical vendor for federal...
- The Defense Logistics Agency awarded a $9,080.88 firm fixed price delivery order to AmerisourceBergen Drug Corp for Repatha 140 mg/ml SureClick auto-injector pens. The award, issued on August 19, 2025, with an ultimate completion date of August 20, 2025, was competitively awarded with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical vendor for federal medical procurement, particularly...
- The Defense Logistics Agency awarded a delivery order valued at $1,325.96 to AmerisourceBergen Drug Corp for Repatha 140 mg/ml SureClick auto-injector pens. This competitive award, issued on November 20, 2025, with an ultimate completion date of November 21, 2025, represents a firm fixed price delivery order with no set-aside designation. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order falls under the company's...
- SPE2DB22D2206Indefinite Delivery Contract
- SPE2DB22D2206-SPE2DB25FJS48Delivery Order
The Defense Logistics Agency awarded a $10,594.36 firm fixed price delivery order to AmerisourceBergen Drug Corp for Repatha 140 mg/ml SureClick auto-injector pens, with an ultimate completion date of September 2, 2025. This non-set-aside award was issued on August 29, 2025, to support federal medical supply needs. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for military and federal healthcare systems. The company maintains a comprehensive portfolio of pharmaceutical and medical supply deliveries through its DLA contracts, encompassing brand-name and generic medications, vaccines, specialty treatments, and medical devices across multiple therapeutic domains. This delivery order for Repatha, a PCSK9 inhibitor used in cardiovascular disease management, exemplifies the company's role in supplying specialized pharmaceutical products to support Defense Health Agency and other federal healthcare operations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $10.6k | 8/29/25 |